Mixed
Accelerated brain aging, specifically measured by a cognition-optimized plasma proteomic model (CognitionBrain), predicts Alzheimer's disease progression and cognitive decline independently of and as strongly as the current best blood biomarker, pTau-181.
For those concerned about Alzheimer's, this research suggests that a new blood test measuring brain-specific aging (CognitionBrain) is just as powerful as the current gold standard (pTau-181) and provides additional, independent information. Using both together offers the best prediction of cognitive decline. This highlights the importance of early, multi-faceted biomarker screening for those with family history or risk factors, rather than relying on a single test.
accelerated brain and vascular aging predict Alzheimer’s disease (AD) progression independently from and as strongly as plasma pTau-181 (ref. 5), the current best blood-based biomarker for AD.
Why this rating
Replicated across multiple cohorts, independent of pTau-181, and additive for risk prediction.
Source
Organ aging signatures in the plasma proteome track health and disease
Hamilton Oh et al. · Nature · 2023
DOI 10.1038/s41586-023-06802-1
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →